> Details

Schupp, Tobias; Behnes, Michael; Weiß, Christel; Nienaber, Christoph; Lang, Siegfried; Reiser, Linda; Bollow, Armin; Taton, Gabriel; Reichelt, Thomas; Ellguth, Dominik; Engelke, Niko; Bertsch, Thomas; Akin, Muharrem; Mashayekhi, Kambis; Borggrefe, Martin; Akin, Ibrahim

Prognostic Impact of Angiotensin-Converting Enzyme Inhibitors and Receptor Blockers on Recurrent Ventricular Tachyarrhythmias and Implantable Cardioverter–Defibrillator Therapies

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Prognostic Impact of Angiotensin-Converting Enzyme Inhibitors and Receptor Blockers on Recurrent Ventricular Tachyarrhythmias and Implantable Cardioverter–Defibrillator Therapies
  • Contributor: Schupp, Tobias; Behnes, Michael; Weiß, Christel; Nienaber, Christoph; Lang, Siegfried; Reiser, Linda; Bollow, Armin; Taton, Gabriel; Reichelt, Thomas; Ellguth, Dominik; Engelke, Niko; Bertsch, Thomas; Akin, Muharrem; Mashayekhi, Kambis; Borggrefe, Martin; Akin, Ibrahim
  • imprint: Ovid Technologies (Wolters Kluwer Health), 2019
  • Published in: Journal of Cardiovascular Pharmacology
  • Language: English
  • DOI: 10.1097/fjc.0000000000000659
  • ISSN: 0160-2446
  • Keywords: Cardiology and Cardiovascular Medicine ; Pharmacology
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract:</jats:title> <jats:p>This study sought to assess the prognostic impact of treatment with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) on recurrences of ventricular tachyarrhythmias in recipients of implantable cardioverter–defibrillators (ICD). Using a large retrospective registry including consecutive ICD recipients with documented episodes of ventricular tachycardia (VT) or fibrillation (VF) from 2002 to 2016, those patients treated with ACEi/ARB were compared with patients without. The primary prognostic endpoint was the first recurrence of ventricular tachyarrhythmias and related ICD therapies at 5 years. Multivariable Cox regression analyses were applied within the entire cohort, and thereafter, Kaplan–Meier analyses were performed in propensity-matched subgroups. A total of 592 consecutive ICD recipients were included (81% treated with ACEi/ARB and 19% without). Although ACEi/ARB was associated with no differences in overall recurrence of ventricular tachyarrhythmias, ACEi/ARB was associated with improved freedom from appropriate ICD therapy within multivariable Cox regressions (hazard ratio = 0.666; <jats:italic toggle="yes">P</jats:italic> = 0.043), especially in patients with index episodes of VF, left ventricular ejection fraction &lt;35%, coronary artery disease, secondary preventive ICD, and glomerular filtration rate &lt;45 mL/min/1.73 m<jats:sup>2</jats:sup>. In the propensity-matched subgroup, ACEi/ARB still prolonged freedom from appropriate ICD therapies (hazard ratio = 0.380; 95% confidence interval 0.193–0.747; <jats:italic toggle="yes">P</jats:italic> = 0.005). In conclusion, ACEi/ARB therapy was associated with improved freedom from appropriate ICD therapies.</jats:p>